Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) have been assigned an average rating of “Hold” from the seventeen research firms that are presently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and six have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $48.67.

IONS has been the subject of several recent research reports. Zacks Investment Research raised shares of Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $59.00 target price for the company in a research note on Monday, July 31st. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and set a $30.00 target price on shares of Ionis Pharmaceuticals in a research note on Friday, October 6th. TheStreet raised shares of Ionis Pharmaceuticals from a “d+” rating to a “c-” rating in a research note on Wednesday, July 5th. Needham & Company LLC reissued a “buy” rating and set a $64.00 target price on shares of Ionis Pharmaceuticals in a research note on Sunday, September 17th. Finally, Barclays PLC initiated coverage on shares of Ionis Pharmaceuticals in a research note on Wednesday, September 6th. They set an “equal weight” rating and a $55.00 target price for the company.

Shares of Ionis Pharmaceuticals (NASDAQ IONS) traded up 0.73% on Friday, hitting $57.73. The company had a trading volume of 1,152,590 shares. The company has a 50-day moving average of $54.28 and a 200 day moving average of $49.49. Ionis Pharmaceuticals has a 12 month low of $24.58 and a 12 month high of $60.01. The stock has a market cap of $7.18 billion, a PE ratio of 277.55 and a beta of 3.12.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Tuesday, August 8th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.03). Ionis Pharmaceuticals had a net margin of 5.25% and a return on equity of 15.52%. The business had revenue of $104.15 million for the quarter, compared to analyst estimates of $93.29 million. During the same period in the prior year, the company earned ($0.47) earnings per share. The firm’s revenue for the quarter was up 170.7% on a year-over-year basis. Analysts anticipate that Ionis Pharmaceuticals will post ($0.17) EPS for the current fiscal year.

In other Ionis Pharmaceuticals news, Chairman Stanley T. Crooke sold 16,500 shares of the stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $52.45, for a total value of $865,425.00. Following the completion of the sale, the chairman now owns 53,014 shares in the company, valued at approximately $2,780,584.30. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP C Frank Bennett sold 10,000 shares of the stock in a transaction that occurred on Monday, July 24th. The stock was sold at an average price of $59.29, for a total transaction of $592,900.00. Following the completion of the sale, the senior vice president now owns 25,041 shares of the company’s stock, valued at approximately $1,484,680.89. The disclosure for this sale can be found here. In the last 90 days, insiders sold 82,000 shares of company stock valued at $4,411,650. 1.86% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in the business. Hanseatic Management Services Inc. lifted its position in Ionis Pharmaceuticals by 1.2% in the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after buying an additional 41 shares in the last quarter. Teacher Retirement System of Texas lifted its position in Ionis Pharmaceuticals by 0.4% in the 2nd quarter. Teacher Retirement System of Texas now owns 9,673 shares of the company’s stock worth $492,000 after buying an additional 43 shares in the last quarter. Public Employees Retirement Association of Colorado lifted its position in Ionis Pharmaceuticals by 0.3% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 24,390 shares of the company’s stock worth $1,241,000 after buying an additional 65 shares in the last quarter. Utah Retirement Systems lifted its position in Ionis Pharmaceuticals by 0.5% in the 1st quarter. Utah Retirement Systems now owns 22,000 shares of the company’s stock worth $884,000 after buying an additional 100 shares in the last quarter. Finally, World Asset Management Inc lifted its position in Ionis Pharmaceuticals by 3.4% in the 2nd quarter. World Asset Management Inc now owns 5,614 shares of the company’s stock worth $286,000 after buying an additional 187 shares in the last quarter. Institutional investors own 89.24% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/12/brokerages-set-ionis-pharmaceuticals-inc-ions-pt-at-48-67.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Analyst Recommendations for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Stock Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.